All In Biotech

Drug Trial Radar · NCT07829588

Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Metastatic Colorectal Cancer

A Randomized, Double-Blind, Parallel-Controlled, Multicenter Phase I Study to Evaluate the Pharmacokinetic Similarity Between QL1203 (Vectibix® Biosimilar Candidate) and Panitumumab (EU-Vectibix®) in Combination With mFOLFOX6 Respectively in Patients With RAS Wild-Type Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

136

Planned (sponsor's estimate)

Start

Nov 24, 2026

Primary completion

Feb 28, 2028

Study completion Aug 30, 2028

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, parallel-controlled, multicenter clinical trial to evaluate the pharmacokinetic similarity between QL1203 and Vectibix® in patients with RAS wild-type metastatic colorectal cancer. Eligible trial participants will be randomized in a 1:1 ratio to either the QL1203 or Vectibix® groups, to received QL1203 + mFOLFOX6 and the control group received Vectibix® + mFOLFOX6. PK profiles, immunogenicity, safety and preliminary efficacy will be evaluated and compared between two groups .

Conditions

  • RAS Wild-type Metastatic Colorectal Cancer

Interventions

  • QL1203 + mFOLFOX6Drug

    QL1203 (6mg/kg) combined with mFOLFOX6, Q2W

  • Vectibix®+ mFOLFOX6Drug

    Vectibix® (6mg/kg) combined with mFOLFOX6, Q2W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUCtau, sdTime frame: through the Cycle 1 (each cycle is 2 weeks)
  2. AUCtau,ss,Time frame: through the Cycle 4 (each cycle is 2 weeks)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.